Cancer stem cell therapy - AbelZeta Pharma/NeoStem Oncology
Alternative Names: Hepatocellular carcinoma stem cell therapy - NeoStem Oncology; Tumor stem cell specific dendritic cell therapy - AbelZeta Pharma; Tumor stem cell specific dendritic cell vaccine - AbelZeta Pharma; Tumour stem cell specific dendritic cell therapy - AbelZeta Pharma; Tumour stem cell specific dendritic cell vaccine - AbelZeta PharmaLatest Information Update: 27 Nov 2023
At a glance
- Originator Hoag Memorial Hospital Presbyterian
- Developer AbelZeta Pharma
- Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies; Stem cell therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver cancer
Most Recent Events
- 20 Nov 2023 Cellular Biomedicine Group is now called AbelZeta Pharma
- 16 Jul 2016 No recent reports of development identified for phase-I development in liver cancer in China (SC, Injection)
- 11 Sep 2014 NeoStem Oncology licenses patents covering methods for use of apoptotic cells to deliver antigen to dendritic cells from Rockefeller University